FDA Brief

Warning letters Drugs

FDA warning letter to

Empower Clinic Services, LLC dba Empower Pharmacy

High riskIssued Sep 18Posted Sep 22Center for Drug Evaluation and Research (CDER)

FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

What happened

FDA inspected Empower Clinic Services, LLC dba Empower Pharmacy in Houston, TX, from November 3, 2025, through November 14, 2025, and issued a Form FDA 483 (inspection observations) on November 14, 2025. FDA collected evidence that the firm compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appeared to be essentially copies of FDA-approved semaglutide and tirzepatide, regularly and in inordinate amounts, with prescription records lacking individualized prescriber determinations of significant difference. FDA also observed sterile production under insanitary conditions and violations of current good manufacturing practice (CGMP), the required manufacturing quality standards, including inadequate smoke studies and media fills and inconsistent media fill records.

What FDA found

  1. The company compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appeared to be essentially copies of FDA-approved semaglutide and tirzepatide, regularly and in inordinate amounts, so they did not qualify for the section 503A exemptions (limited exceptions for compounded drugs).

    FD&C Act §§ 503A(b)(1)(D), 503A(b)(2) [21 U.S.C. §§ 353a(b)(1)(D), 353a(b)(2)]
  2. The company marketed these compounded drugs without FDA-approved new drug applications.

    FD&C Act §§ 505(a), 301(d) [21 U.S.C. §§ 355(a), 331(d)]
  3. Sterile drug products were prepared under insanitary conditions because smoke studies did not adequately show unidirectional airflow in the ISO 5 area.

    FD&C Act § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. Media fills were not performed under the most challenging or stressful conditions, so there was insufficient assurance of aseptic production.

    FD&C Act § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. The firm failed to establish and follow written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  6. The quality control unit failed to ensure drug products complied with CGMP and met specifications for identity, strength, quality, and purity.

    21 CFR 211.22

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, explain how recurrence will be prevented, and include related documentation; if the company cannot fully address the matter in that time, it must state why and give a timeframe. FDA also strongly recommends a comprehensive management assessment of operations, especially aseptic processing, with a third-party consultant who has sterile drug manufacturing expertise.

Who should pay attention

  • clinics and prescribers ordering compounded semaglutide or tirzepatide
  • patients using compounded semaglutide or tirzepatide injections
  • other pharmacies making sterile compounded drugs

This is a summary. Read the original letter on fda.gov.

Empower Clinic Services, LLC dba Empower Pharmacy's FDA history

  1. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.

    High risk
  2. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.

    Medium

Full company page

Similar letters to other companies

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  3. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low